Trial Search Results

Zoledronic Acid With Intermittent Hormonal Therapy in Patients With Prostate Cancer


To determine the duration of use of zoledronic acid in improving Bone mineral density in patients with prostate cancer who are on hormones intermittently.

Secondary Objectives:

To describe the safety and tolerability at this dose and schedule

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Collaborator: Novartis

Stanford Investigator(s):


  • Drug: zoledronic acid


Phase 2


Inclusion Criteria:Patients: Who are 18 years of age and older Who have histologically
documented adenocarcinoma of prostate Who are currently receiving LHRH agonists KPS greater
than 80%Life expectancy greater than 6 months Provide written consent pursuant to
regulatory requirements prior to initiation of study procedure

Exclusion Criteria:Exclusion Criteria: Patients: Any patient requiring continuous LHRH Any
patient who has had an orchiectomy Any patient with painful bone metastases Who have
received chemotherapy for prostate cancer Who have a abnormal serum creatine >2.5 Receiving
any investigational drug within the last 28 days Severe uncontrolled infection, diabetes,
cardiac disease Patients with fragility fractures, hyperparathyroidism, Pagets renal
osteodystrophy will be excluded History of non compliance to medical regimens or
unwillingness to return for medical visits

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Denise Haas
Not Recruiting